SARGRAMOSTIM for Adrenal gland cancer: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 26 adverse event reports in the FDA FAERS database where SARGRAMOSTIM was used for Adrenal gland cancer.
Most Reported Side Effects for SARGRAMOSTIM
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 98 | 16.5% | 12 | 10 |
| Pyrexia | 76 | 12.8% | 3 | 23 |
| Pain | 56 | 9.4% | 2 | 1 |
| Hospitalisation | 31 | 5.2% | 0 | 24 |
| Death | 30 | 5.1% | 29 | 0 |
| Hypotension | 25 | 4.2% | 3 | 18 |
| Device related infection | 23 | 3.9% | 1 | 1 |
| Cough | 20 | 3.4% | 1 | 4 |
| Febrile neutropenia | 20 | 3.4% | 1 | 5 |
| Disease progression | 18 | 3.0% | 9 | 1 |
| Device related bacteraemia | 17 | 2.9% | 0 | 0 |
| Fatigue | 16 | 2.7% | 1 | 8 |
| Hypersensitivity | 16 | 2.7% | 0 | 4 |
| Nausea | 16 | 2.7% | 3 | 2 |
| Injection site erythema | 14 | 2.4% | 0 | 0 |
Other Indications for SARGRAMOSTIM
Neuroblastoma (88)
Product used for unknown indication (48)
Alveolar proteinosis (44)
Pancreatic carcinoma (40)
Pancreatic carcinoma metastatic (39)
Neutropenia (35)
Malignant melanoma (24)
Prostate cancer (17)
Neoplasm malignant (12)
Bladder cancer (7)
Other Drugs Used for Adrenal gland cancer
MITOTANE (250)
CABOZANTINIB S-MALATE (104)
PEMBROLIZUMAB (56)
ETOPOSIDE (34)
METYRAPONE (33)
CISPLATIN (32)
NIVOLUMAB (32)
DOXORUBICIN (31)
SUNITINIB MALATE (27)
IPILIMUMAB (21)